Physiogenix, Inc.

Wauwatosa, WI 53226

SBIR Award Summary

Total Number of Awards 16
Total Value of Awards $5.05MM
First Award Date 04/15/02
Most Recent Award Date 09/15/10

Key Personnel

Last Name Name Awards Contact
Nye Steven H Nye 15
Gibbs Earl Michael Gibbs 1

16 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-142
Budget: 09/15/10 - 03/14/12

DESCRIPTION (provided by applicant): The number of patients in the United States afflicted with learning and memory disorders is rapidly increasing. This necessitates the development of new, better acting and safer medications for enhancing cognition. In this SBIR Phase I project, PhysioGenix will determine the efficacy, pharmacokinetics (PK), ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AA-06-01
Budget: 09/25/08 - 02/28/09

DESCRIPTION (provided by applicant): This SBIR project combines the use of genetic models with genomic, proteomic and metabolomic technologies as a solution to discover molecular fingerprints as biomarkers for alcohol-induced organ damage. While several classic biomarkers have been used by clinicians, there is no genetic or biochemical test that...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 06/15/08 - 02/28/10

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 03/01/08 - 02/28/10

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 03/01/07 - 02/29/08

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AA-06-01
Budget: 09/10/06 - 02/28/09

DESCRIPTION (provided by applicant): This SBIR project combines the use of genetic models with genomic, proteomic and metabolomic technologies as a solution to discover molecular fingerprints as biomarkers for alcohol-induced organ damage. While several classic biomarkers have been used by clinicians, there is no genetic or biochemical test that...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/01/06 - 02/28/07

DESCRIPTION (provided by applicant): PhysioGenix plans to commercialize a rat discovery platform that markedly accelerates the deployment of genetic tools for drug development by Pharma. While genetics can offer pharmaceutical companies a powerful discovery tool, this strategy has not been widely adopted because traditional methods are too slow....

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/05 - 07/31/07

DESCRIPTION (provided by applicant): This Phase I SBIR project uses a new Quality Control microarray (QCarray) technology to generate Drug Toxicity Signatures (DTSs) for predicting liver toxicity in rat. The QCarray enables each element on every array to have a quality control (QC) score and markedly reduces a common source of error: fabrica...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 07/31/05

DESCRIPTION (provided by applicant): The concept of a pre-clinical, drug screen for genetic effects was developed by PhysioGenix in Phase I of this project. The screen consists of inbred rats bred in a combinatorial fashion such that F1 offspring mimic the genetically diverse human population, while maintaining the phenotypic accuracy of an inbr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/04 - 07/31/05

DESCRIPTION (provided by applicant): This Phase I SBIR project uses a new Quality Control microarray (QCarray) technology to generate Drug Toxicity Signatures (DTSs) for predicting liver toxicity in rat. The QCarray enables each element on every array to have a quality control (QC) score and markedly reduces a common source of error: fabrica...

Load More